Basic Metabolic Panel

Serum glucose reflects the moment-to-moment balance between hepatic output, intestinal absorption, and peripheral uptake, governed chiefly by insulin and the counter-regulatory hormones glucagon, cortisol, and catecholamines. On a metabolic panel it is a single-timepoint snapshot rather than an integrated measure, which is why it is read against the fasting state recorded at collection.

Glucose anchors the metabolic half of the panel. A fasting value in the impaired range or above flags dysglycaemia and prompts confirmatory testing with HbA1c or repeat fasting glucose, while a low value in a symptomatic patient raises hypoglycaemia. Because it sits alongside electrolytes and renal markers here, glucose also contributes to the osmolar picture and to recognition of hyperglycaemic crises.

Total calcium measures protein-bound, complexed, and free ionised fractions together, roughly half of it bound to albumin. Circulating concentration is held within a narrow band by parathyroid hormone, 1,25-dihydroxyvitamin D, and renal handling. Because the bound fraction tracks albumin, a low albumin lowers total calcium without changing the physiologically active ionised fraction.

On the panel, calcium is a screen for disturbances of the parathyroid–vitamin D–renal axis. An elevated value prompts consideration of primary hyperparathyroidism or malignancy; a low value points toward hypoparathyroidism, vitamin D deficiency, or renal loss. Correction for albumin — or direct ionised calcium — is needed before acting on a borderline total calcium.

Sodium is the principal extracellular cation and the dominant determinant of plasma osmolality and extracellular volume. Its concentration is regulated less by sodium intake than by water balance — through antidiuretic hormone, thirst, and renal free-water handling — so a measured sodium abnormality is most often a disorder of water, not of total body sodium.

Sodium is interpreted as part of the electrolyte and acid-base cluster rather than alone. Hyponatraemia is read with volume status and, where available, serum and urine osmolality to separate hypovolaemic, euvolaemic, and hypervolaemic causes; hypernatraemia signals a water deficit. The rate of change matters as much as the absolute value because of the risk of osmotic demyelination with over-rapid correction.

Potassium is overwhelmingly intracellular; the small extracellular fraction measured here is maintained by the sodium–potassium ATPase, renal excretion under aldosterone, and acute shifts driven by acid-base status, insulin, and beta-adrenergic tone. Small changes in the measured value therefore reflect large shifts in whole-body distribution or excretion.

Because of its narrow tolerance and effect on cardiac and neuromuscular membranes, potassium is among the most consequential values on the panel. It is interpreted with bicarbonate and the acid-base picture, with renal function, and against the patient's medications. Pseudohyperkalaemia from haemolysis or delayed processing must be excluded before a high result is acted upon.

Chloride is the major extracellular anion and tends to move with sodium and inversely with bicarbonate to preserve electroneutrality. Its handling is tied to renal acid-base regulation, so chloride shifts are often the mirror image of changes in bicarbonate.

Chloride is most informative in combination: it is a component of the calculated anion gap and helps characterise metabolic acidosis as high-gap or normal-gap (hyperchloraemic). Isolated chloride abnormalities are seldom actionable on their own, but the sodium–chloride–bicarbonate relationship is central to reading the acid-base pattern of the panel.

The total CO2 reported on a metabolic panel is predominantly serum bicarbonate, the metabolic component of acid-base balance regulated by the kidney. It falls when acid accumulates or bicarbonate is lost and rises with metabolic alkalosis or as renal compensation for chronic respiratory acidosis.

Bicarbonate is the panel's window onto acid-base status. Read with chloride and the anion gap it distinguishes high-gap from normal-gap metabolic acidosis; read with potassium it helps explain transcellular shifts. A venous total CO2 is a screen rather than a substitute for arterial blood gas analysis when a precise acid-base assessment is required.

Urea is the hepatic end-product of protein catabolism, cleared largely by glomerular filtration with variable tubular reabsorption that rises when renal perfusion falls. BUN therefore responds not only to glomerular filtration but also to protein intake, catabolic state, gastrointestinal bleeding, and hydration — making it a less specific renal marker than creatinine.

BUN earns its place by its interaction with the rest of the panel. A disproportionate rise relative to creatinine (a high BUN:creatinine ratio) suggests a pre-renal, volume-responsive picture, whereas a proportionate rise points to intrinsic renal impairment. It is interpreted with creatinine, eGFR, and the electrolytes rather than as a standalone kidney test.

Creatinine is a steady-state product of muscle creatine turnover, filtered by the glomerulus and minimally reabsorbed, which makes its serum concentration a usable inverse index of glomerular filtration. Because production scales with muscle mass, a given creatinine means different filtration in a frail older adult than in a muscular young patient.

Creatinine is the panel's primary renal marker and the input to estimated GFR. It is interpreted with BUN, the BUN:creatinine ratio, and potassium and bicarbonate, since impaired filtration disturbs the whole electrolyte and acid-base picture. A single value defines a baseline; trend and the clinical trajectory distinguish acute from chronic change.

eGFR is not measured but computed from serum creatinine together with age and sex using a validated estimating equation (the race-free 2021 CKD-EPI creatinine equation in current practice). It converts a concentration into an estimate of filtering capacity standardised to body surface area, and inherits every limitation of creatinine — notably its dependence on muscle mass and its lag during rapidly changing function.

As the panel's derived renal value, eGFR translates creatinine into a clinically graded estimate of kidney function used to stage chronic kidney disease, adjust drug dosing, and trigger nephrology input. It is read with creatinine trend, BUN, and the electrolyte and acid-base pattern; a stable estimate below the threshold over at least three months is required before chronic kidney disease is inferred from the panel alone.